Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.
Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.
The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.
The main information that researchers will collect in this study:
* Age, gender, and other information about the child and their illness
* Type of VTE treatment given to the child
* Occurrence of medically important bleeding and its severity
Further information that researchers will collect:
* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
* Return of VTE symptoms
* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.
The data for this study will be collected from electronic health records and health insurance claims data until 2026.
Researchers will observe each child during treatment until:
* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
* their information is no longer available, or
* the study ends.

Start Date31 Dec 2025

Sponsor / Collaborator

Bayer AG

[+1]

TCTR20240719002

/ Not yet recruitingPhase 1IIT

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Rivaroxaban 20 mg tablets relative to Xarelto 20 mg tablets, in healthy Thai volunteers under fed condition.

Start Date12 Jul 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

NCT06780462

/ Not yet recruitingPhase 3IIT

Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability.
Post Thrombotic Syndrome (PTS) is frequent especially with recurrent episodes of deep vein thrombosis and may result in leg ulcers that are very difficult to treat. Vascular involvement is a major cause of morbidity and mortality among BS patients. However, one of the most controversial issues regarding the management of BS is whether DVT should be treated with anticoagulants. Moreover, use of anticoagulants exposes patients to serious bleeding, especially in those who presents simultaneous arterial aneurysms. However, many physicians are still using anticoagulants. This is the first prospective, randomized study assessing benefits of corticosteroids associated with anticoagulant compared to that of corticosteroids alone in DVT in BS patients. It will validate or not the use of anticoagulants in those situations. It will allow a direct comparison of the safety profile of those two schemes of treatment.

Start Date15 Jan 2025

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

100 Clinical Results associated with Rivaroxaban

100 Translational Medicine associated with Rivaroxaban

100 Patents (Medical) associated with Rivaroxaban

8,020

Literatures (Medical) associated with Rivaroxaban

01 Mar 2025·AMERICAN HEART JOURNAL

A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia

Article

Author: Sierra-Lara Martínez, Jorge Daniel ; Nájera-Rojas, Nitzha Andrea ; Grimaldo-Gomez, Flavio Adrian ; Piña-Reyna, Yigal ; Latapi-Ruiz Esparza, Ximena ; Romero-Arroyo, María Oliva ; Alfaro-Ponce, Diana Laura ; González-Pacheco, Héctor ; Gopar-Nieto, Rodrigo ; Martínez-Ríos, Marco Antonio ; Araiza-Garaygordobil, Diego ; Arias-Mendoza, Alexandra ; Ruiz-Beltrán, Maximiliano ; Sarabia-Chao, Vianney ; Cortina-De la Rosa, Evelyn ; Sierra-Gonzalez de Cossio, Alejandro ; Mullasari, Ajit S ; Belderrain-Morales, Nallely ; Diaz-Herrera, Braiana Angeles ; Briseño-De la Cruz, Jose Luis

BACKGROUND:

Coronary artery ectasia (CAE) of the culprit infarct artery is a rare finding in patients with acute coronary syndrome (ACS). While anticoagulants have been suggested to reduce recurrent events, the optimal antithrombotic therapy remains unclear.

METHODS:

OVER-TIME was an open label, exploratory, randomized controlled trial comparing dual antiplatelet therapy (DAPT; acetyl-salicylic-acid 100mg plus clopidogrel 75mg daily) versus single antiplatelet (SAPT, clopidogrel 75mg) plus DOAC (rivaroxaban 15mg) in patients with ACS and CAE. The study primary objectives were 1) the composite of cardiovascular death, recurrent MI and repeat revascularization and 2) total bleeding events (BARC 1-5) at 12 months. The secondary objective was fibrin clot lysis time (using turbidimetry).

RESULTS:

A total of 62 patients were randomized, 32 (51.6%) to receive DAPT and 30 (48.3%) to receive SAPT+DOAC. Patients were aged 55.5 years (±10.6) and mostly male (86.9%); STEMI was the most common presentation (83.8%). No statistically significant differences (HR 0.24, 95% CI 0.02-2.16, P = .20) in the risk of the primary endpoint were found; however, a numerically lower rate of recurrent MI (4 events - 12.5% - in the DAPT arm vs. 1 event - 3.3% in the SAPT+DOAC arm) was observed. The risk of bleeding events was not different HR 0.75 (95% CI 0.26-2.16, P = .59). A statistically significant reduction in fibrin clot lysis time (-24.7% reduction, P = .038) was observed in those randomized to SAPT+DOAC, but not in DAPT (-14.7% reduction, P = .25).

CONCLUSIONS:

In this exploratory study including patients with ACS and CAE of the culprit artery, the use of rivaroxaban 15mg in addition to clopidogrel was not associated with a statistically lower risk of major adverse cardiovascular events; however, a lower rate of recurrent MI and a reduction in fibrin clot lysis time were observed. Future studies to address antithrombotic therapy in CAE are needed.

TRIAL REGISTRATION:

ClinicalTrials.gov ID NCT05233124, URL: https://clinicaltrials.gov/study/NCT05233124.

01 Feb 2025·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review

Review

Author: Arabloo, Jalal ; Makhtoumi, Vahid ; Rezapour, Aziz ; Sadiani, Zahra Mollaei ; Rezaei, Mohammad Ali

PURPOSE:

This study aimed to systematically review the cost-effectiveness of rivaroxaban plus aspirin (RIV + ASA) versus aspirin (ASA) alone in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD).

METHODS:

A systematic review was conducted using leading databases including PubMed, Scopus, and Web of Science core collection. The search was carried out up to June 25, 2024, focusing on identifying full economic evaluation studies comparing the cost-effectiveness of RIV + ASA versus ASA alone in patients with stable cardiovascular diseases (CVDs). The methodological quality of the included studies was assessed utilizing the validated Quality of Health Economics Studies (QHES) checklist. Subsequently, a qualitative analysis was performed to synthesize the collected data. We converted the incremental cost-effectiveness ratios (ICERs) into the equivalent amount in US dollars for the year 2024.

RESULTS:

Out of 315 identified articles, 11 met inclusion criteria and were included in the review. RIV + ASA was generally found to be cost-effective, with ICERs falling within acceptable willingness-to-pay (WTP) thresholds. However, substantial variation in ICERs was observed across studies due to differences in healthcare systems, drug pricing, and WTP thresholds. In these studies, ICERs per quality-adjusted life-year (QALY) were (in 2024 US dollars) US$4939 to $29,162 for all patients, $10,385 to $85,394 for CAD, and $1013 to $40,244 for PAD in different studies. RIV + ASA was more cost-effective in high-risk subgroups, such as patients with PAD. Key drivers of cost-effectiveness included mortality rates, the cost of rivaroxaban, and utility scores.

CONCLUSIONS:

RIV + ASA appears to be a cost-effective treatment option for patients with CAD or PAD or both. Future research should address geographical biases, consider societal perspectives, and explore alternative treatment options to optimize resource allocation and improve patient outcomes in the management of CVDs. Future research should also consider evaluating the cost-effectiveness of alternative new oral anticoagulants (NOACs) to provide a broader perspective on treatment options for CVD.

01 Feb 2025·Journal of Arrhythmia

Real‐world clinical practice of current periprocedural anticoagulation management in catheter ablation of atrial fibrillation: Data from a large prospective ablation registry

Article

Author: Nakajima, Jun ; Hirao, Kenzo ; Tanaka, Yasuaki ; Shirai, Yasuhiro ; Tao, Susumu ; Okada, Hiroyuki ; Miyazaki, Shinsuke ; Hachiya, Hitoshi ; Inaba, Osamu ; Handa, Keita ; Nitta, Junichi ; Ono, Yuichi ; Nagata, Yasutoshi ; Nishimura, Takuro ; Sekiguchi, Yukio ; Suzuki, Makoto ; Iwai, Shinsuke ; Takigawa, Masateru ; Suzuki, Atsushi ; Takahashi, Atsushi ; Sasaki, Takeshi ; Inamura, Yukihiro ; Mizukami, Akira ; Taomoto, Yuta ; Azegami, Koji ; Yamauchi, Yasuteru ; Sasano, Tetsuo ; Sagawa, Yuichiro

Abstract:

Background:

The guidelines recommend anticoagulation management with uninterrupted warfarin or direct thrombin inhibitors (DTIs) during the atrial fibrillation (AF) ablation periprocedural period.

Objectives:

To clarify the Japanese real‐world latest periprocedural anticoagulation management during AF ablation.

Methods:

This multicenter observational study included 6232 consecutive AF patients (68.7 ± 10.9 years, 4346 men) who underwent periprocedural anticoagulation therapy using direct oral anticoagulants (DOACs) between January 2022 and August 2023.

Results:

The mean CHADS2 and CHA2DS2VASc scores were 1.2 ± 1.1 and 2.3 ± 1.5. Bleeding and thromboembolic events occurred in 79 (1.3%) and eight (0.12%) patients. During the periprocedural period, factor Xa inhibitors (FXaIs) were used in 3063 patients (rivaroxaban in 624, apixaban in 1093, and edoxaban in 1345) and DTIs in 3170 including 2583 in whom DTIs were switched from FXaIs. Both the bleeding (0.85% vs. 1.69%, p = .003) and thromboembolic event rates (0.03% vs. 0.23%, p = .036) were significantly lower in the DTI‐ than FXaI‐group. A multivariate analysis showed periprocedural FXaI use was significantly associated with both bleeding events (odds ratio [OR] = 1.92, 95% confidence interval [CI] = 1.20–3.08, p = .006) and cardiac tamponade (OR = 2.74, 95% CI = 1.27–5.9, p = .01). The interval between the last DOAC administration and the procedure was significantly shorter in the DTI‐ than FXaI‐group (4.2 ± 4.9 vs. 19.3 ± 10.7 h, p < .01). In the FXaI‐group, the bleeding rate tended to be lower in the minimally interrupted (n = 2105) than uninterrupted group (n = 821) (1.47% vs. 2.56%, p = .06). Two patients in the uninterrupted FXaI‐group required surgical management for cardiac tamponade.

Conclusions:

Our multicenter real‐world data demonstrated that anticoagulation with DTIs was a reasonable periprocedural anticoagulation regimen to reduce periprocedural complications.

200

News (Medical) associated with Rivaroxaban

15 Jan 2025

·endpts.com

Drugmakers tout limits of IRA impact ahead of next negotiation round

Johnson & Johnson, AstraZeneca and Pfizer leaders reiterated during the JP Morgan Healthcare Conference that the federal government’s price negotiations still won’t have a material effect on their bottom lines. As early as this week, CMS may release the names of the next 15 drugs subject to Medicare drug price negotiations for 2027. The Trump administration is taking over on Monday. J&J CEO Joaquin Duato said Monday during a fireside chat that the company’s revenue estimate for 2025 includes the IRA’s impact. J&J’s Xarelto, Stelara, and Imbruvica were among the drugs selected in the first round of negotiations for 2026, and Duato says those products “are not core to our growth.” “So we feel confident about being able to deliver in our estimates,” he said, according to an AlphaSense transcript. The IRA-negotiated prices for a 30-day supply of J&J’s drugs for 2026 are: $197 for Xarelto, $4,695 for Stelara and $9,319 for Imbruvica. Those prices are 62%, 66% and 38% lower than the drugs’ list prices, respectively. AstraZeneca’s chief financial officer and executive director Aradhana Sarin noted in a presentation on Tuesday that the company faces “headwinds,” including “pricing pressures” and the IRA. But she said she still expects “the base business to have strong momentum in terms of revenue going into 2025,” according to an AlphaSense transcript. Sarin said the company expects total revenue to rise by a “high teens percentage,” and that it will report its full-year results on Feb. 6. AstraZeneca’s blockbuster drug Farxiga was included in the first round of negotiations and has a negotiated price of $178, or 68% lower than the list price. Meanwhile, Pfizer CEO Albert Bourla said during a fireside chat that he expects a “$1 billion negative impact because of the IRA,” according to an AlphaSense transcript. He still says he expects “strong performance” from the company’s newer acquisition products, including Biohaven Pharmaceuticals’ migraine drug Nurtec. “The IRA clearly affects us, but there are also many bigger things that are affected by [the] IRA, which is the tech and all the renewables and a lot of the stuff. For a complete rebuild … I don’t know if they would go for anything like that now, but improvements on the IRA we will certainly advocate for,” Bourla said during a lunch with reporters. Pfizer’s Eliquis was included in the first round of IRA drug price negotiations and has a negotiated price of $231, which is 56% lower than the list price. The IRA’s other drug pricing provisions include a $2,000 annual out-of-pocket cap and new manufacturer discounts, among other provisions. Pfizer said in a December press release that it expects an unfavorable impact from a new manufacturer discount program , which requires companies to provide certain discounts on applicable drugs to Medicare beneficiaries. The first round of negotiations, which ended in August, is expected to save Medicare $6 billion in 2026. Negotiated prices for the second round of drugs are slated to take effect on Jan. 1, 2027, according to CMS guidance. Manufacturers of the second round’s selected drugs have until Feb. 28 to agree to participate in the negotiations. — Jaimy Lee contributed reporting.

20 Dec 2024

·www.echemi.com

AstraZeneca's Andexxa Denied Full FDA Approval

Recently, AstraZeneca announced that the FDA has rejected its application for full approval of the drug Andexxa. Andexxa was submitted for market approval in China in December 2022. Initially, it received accelerated approval from the FDA in 2018 and conditional approval from the European Union in 2019. It is primarily used to treat acute bleeding caused by apixaban and rivaroxaban and is the only drug that can specifically reverse the activity of FXa inhibitors, hence being referred to as a "life-saving drug." In 2021, AstraZeneca acquired Alexion for $39 billion, which made Andexxa part of its product line. Reports indicate that Andexxa generated sales of $182 million in 2022, marking a 23% year-on-year increase. The FDA's reason for rejection was that the data provided by AstraZeneca revealed a "significant safety issue": the thrombosis-related mortality rate among patients using Andexxa was twice that of standard treatment. AstraZeneca stated that Andexxa will remain on the U.S. market and plans to collect further data to address the FDA's concerns. If subsequent data is unfavorable, there is a risk of withdrawal from the market. This decision could affect Andexxa's fate in other markets. Currently, its application for market approval in China is still pending, and in March next year, Andexxa's conditional approval in the EU may face stricter scrutiny. "Savage" Drug Reversal Agent With the rapid growth of Xa factor inhibitors such as rivaroxaban and apixaban in thrombotic treatment, these drugs have quickly replaced warfarin as the mainstream anticoagulants. In 2019, the combined sales of rivaroxaban and apixaban reached $16.4 billion, but complaints about bleeding events have also increased. As an antidote to reverse the anticoagulant effects of "saban" drugs, Andexxa can quickly reverse their impact. In 2020, Alexion acquired Andexxa for $1.4 billion, and it subsequently fell under AstraZeneca's umbrella. AstraZeneca has high hopes for Andexxa, with sales continuing to grow, reaching $182 million globally in 2023, a 24% year-on-year increase in the first three quarters. The company is advancing post-marketing clinical trials to seek comprehensive approval. Continuing to Seek Full Approval Industry insiders were surprised by the FDA's rejection. The ANNEXA-I trial conducted in June 2023 showed that Andexxa performed well in hemostatic capability, leading AstraZeneca to terminate the clinical trial early. However, the FDA advisory committee pointed out that the incidence of thrombosis significantly increased among patients using Andexxa. Nevertheless, the FDA's stance was not entirely resolute; committee members suggested modifying the indications and dosage to better assess Andexxa's safety. Currently, AstraZeneca plans to present complete efficacy and safety data at the upcoming medical conference. If supplemental data supports its safety, Andexxa's future remains promising.

Drug ApprovalAcquisitionClinical StudyAccelerated Approval

17 Dec 2024

·www.accesswire.com

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000.The combined institutes have led over 1,250 studies, published 5,500 manuscripts in peer review literature (including 144 in the New England Journal of Medicine) and have led 70 FDA submissions from their network of 7,000 sites in 57 countries worldwide. Since 2014, Gibson has consistently been ranked as one of the world's most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 170,000 times."Lexaria's drug delivery technology offers exciting new pathways towards improving pharmacokinetic drug performance that could unlock a new era of reduced drug waste and adverse side effects combined with enhanced efficacy," said Dr. Gibson. "I'm excited to pursue new and improved applications for this exciting technology.""Dr. Gibson has a wealth of knowledge and experience that will benefit Lexaria, particularly in the area of hypertension which remains an area of intense interest for Lexaria," said John Docherty, President. "On behalf of everyone at Lexaria, I welcome Dr. Gibson's contributions as our new Chief Medial Advisor and member of our scientific advisory board."As Chief Medical Advisor, Dr. Gibson will participate with other scientific and medical experts within Lexaria's newly-formed scientific advisory board in pursuing Lexaria's prioritized objectives in the fields of drug delivery optimization.Dr. Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 34,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack. He founded WikiDoc.org and WikiPatient.org and is Editor-In-Chief of over 2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 15 years. Gibson also founded www.clinicaltrialresults.org. Gibson serves as Chief Medical Correspondent for the American College of Cardiology. Gibson has over 435,000 followers on social media where he is a leading influencer, second only to Sanjay Gupta in some pollsAbout Lexaria Bioscience Corp. & DehydraTECHDehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.CAUTION REGARDING FORWARD-LOOKING STATEMENTSThis press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.INVESTOR CONTACT:George Jurcic - Head of Investor Relations[email protected]Phone: 250-765-6424, ext 202SOURCE: Lexaria Bioscience Corp.

Executive Change

100 Deals associated with Rivaroxaban

External Link

KEGG	Wiki	ATC	Drug Bank
D07086	Rivaroxaban	B01AF01	DB06228

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thromboembolism	JP	Bayer Yakuhin Ltd.	24 Nov 2023
Thrombosis	US	Janssen Pharmaceuticals, Inc.	20 Dec 2021
Atherosclerosis	EU	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	IS	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	LI	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	NO	Viatris Ltd. (New Zealand)	12 Nov 2021
Atrial Fibrillation	CN	Bayer AG	31 Mar 2009
Myocardial Infarction	AU	Bayer Australia Ltd.	24 Nov 2008
Recurrent deep vein thrombosis	AU	Bayer Australia Ltd.	24 Nov 2008
Stroke	AU	Bayer Australia Ltd.	24 Nov 2008
Systemic embolism	AU	Bayer Australia Ltd.	24 Nov 2008
Acute Coronary Syndrome	EU	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	IS	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	LI	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	NO	Bayer AG	30 Sep 2008
Embolism	EU	Bayer AG	30 Sep 2008
Embolism	IS	Bayer AG	30 Sep 2008
Embolism	LI	Bayer AG	30 Sep 2008
Embolism	NO	Bayer AG	30 Sep 2008
Peripheral arterial occlusive disease	EU	Bayer AG	30 Sep 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	AU	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	CA	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	FR	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	IN	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	MY	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	SA	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	SG	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	TW	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	TN	Bayer AG	14 Dec 2020
Chronic Kidney Diseases	Phase 3	AU	Bayer AG	14 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03746301 (XARENAL, Pubmed \| Korean Circ J)	Not Applicable	renal impairment \| creatinine clearance \| estimated glomerular filtration rate	888	Rivaroxaban	qkxskuwyfh(qudhugwpmc) = usmmgansul bbzvkmtwle (vqldastkqk ) View more	Positive	01 Jan 2025
697 (ASH2024)	Not Applicable	Pulmonary Embolism	-	Rivaroxaban 15 mg or 20 mg	lzamnmxjfd(pfycjsupil) = ekphcprrpy ygfgzntqrr (gkhyjulxfn )	Positive	08 Dec 2024
				Warfarin	lzamnmxjfd(pfycjsupil) = hbqbiagwdw ygfgzntqrr (gkhyjulxfn )
ASH2024	Not Applicable	Thromboembolism	-	Prophylactic dose apixaban (2.5 mg twice daily)	hczdezhufy(eugyeozyol) = tqbdecoedg alizotfiqr (onmocwcwnm, 6.4 - 12.6) View more	-	08 Dec 2024
				Therapeutic dose apixaban (5 mg twice daily)	hczdezhufy(eugyeozyol) = azslhinpmd alizotfiqr (onmocwcwnm, 14.8 - 19.8) View more
NCT02024230 (REWRAPS, ESC2024)	Phase 4	Coronary Artery Disease \| Atrial Fibrillation \| Chronic Kidney Diseases	493	Rivaroxaban	pbxuniaqqv(hzztlxmztj) = grljbatnrc taqljiuyef (msyonfznwm, 0.55 - 1.11) View more	Positive	02 Sep 2024
				Warfarin	pbxuniaqqv(hzztlxmztj) = gykwemnmqi taqljiuyef (msyonfznwm, 0.55 - 1.11) View more
NCT04970381 (R-DISSOLVE, CTgov)	Not Applicable	Thrombosis	75	rivaroxaban	nvuongypas(bcklnnlaqo) = uuloqvefpt phbqakcrok (maiugontsh, btilqtwxaq - owfuqeuylv) View more	-	02 Aug 2024
NCT01606995 \| NCT01800006 \| NCT01750788 (XANTUS, Pubmed \| Europace)	Not Applicable	Atrial Fibrillation	-	Rivaroxaban	tyjtvonvhk(xlawsfocyc) = oayomofksz otrcoajjsn (slptknaoyd ) View more	-	02 Jul 2024
ChiCTR2000031649 (ASCO2024) Manual	Phase 2	Breast Cancer	402	Rivaroxaban 10 mg	lfpjhrmcby(jpfvkwapfy) = wuzlurqkxi auoliuefll (kifwxnfgon )	Positive	24 May 2024
				rivaroxaban (Control group (no prophylactic anticoagulation))	lfpjhrmcby(jpfvkwapfy) = nqlmlzfqmk auoliuefll (kifwxnfgon )
SAVED and IMPEDE VTE (ASCO2024)	Not Applicable	Multiple Myeloma SAVED score \| IMPEDE score	347	Aspirin	xildrvaegn(qvpaqepgsk) = ndbcnrwozp uzzvnfucat (jzxileaoqc )	Positive	24 May 2024
				Apixaban	xildrvaegn(qvpaqepgsk) = hsfizyfynp uzzvnfucat (jzxileaoqc )
NCT05150938 (Pubmed)	Not Applicable	Venous Thromboembolism	-	Rivaroxaban	nlqamxdchk(lovzycnucd) = kfqfhmeypy rqontodgdu (mrxavqpyit, 103.9 - 201.5) View more	Positive	12 May 2024
				Low Molecular Weight Heparin (LMWH)	nlqamxdchk(lovzycnucd) = knktwyesja rqontodgdu (mrxavqpyit, 541.8 - 590.2) View more
NCT04356989 (XARETO, ESC2024)	Not Applicable	Renal Insufficiency \| Atrial Fibrillation	493	Rivaroxaban	xnhvgghghj(rvqurnutvb) = ewpmmpepse cquiqhiwnz (fszlwibqha )	Positive	07 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis